BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Tecan and Luminex Corporation (LMNX) Partner to Develop Automated Newborn Screening Solution


10/12/2010 2:00:19 PM

MANNEDORF, SWITZERLAND--(Marketwire - October 12, 2010) -


Tecan Group AG /

Tecan Group and Luminex Corporation Partner to Develop Automated Newborn Screening Solution

Processed and transmitted by Thomson Reuters.

The issuer is solely responsible for the content of this announcement.

New solution combines multiplexing and automation technologies to create novel system that provides faster results and saves valuable time and resources in newborn screening laboratories

Männedorf, Switzerland, and Austin, Texas - October 12, 2010 - The Tecan Group (SWISS: TECN) and Luminex Corporation (NASDAQ: LMNX) have announced that they will collaborate on the development of a new automated newborn screening solution that will provide faster results for infants' potential health concerns. The companies have entered into a global OEM agreement that allows them to combine Luminex® xMAP® technology and LX 200™ instrument with Tecan's flexible and reliable Freedom EVO® liquid handling platform and HydroFlex™ washer. The new automated newborn screening solution will help laboratories enhance efficiency, save vital resources and analyze more samples more quickly. Luminex expects to launch the automated newborn screening solution in 2011.

Thomas Bachmann, CEO of Tecan, said: "We are delighted that we have been chosen by Luminex to supply a fully automated solution for such an important application. This global OEM agreement is building on a long, well established partnership of creating the most advanced automated solutions in the research market for Luminex xMAP technology."

Luminex xMAP technology enables large numbers of biological tests to be conducted simultaneously and analyzed quickly, cost-effectively and accurately. Once it receives regulatory clearance, NeoPlex4™ will be a fully automated, walk-away testing platform for multiplexed newborn screening. These high-volume screening assays test newborn infants for several different biomarkers linked to critical diseases. Each of these conditions can cause severe mental and physical disability if untreated. If detected early through testing, effective treatment can be initiated. Multiplexing these tests together from one sample offers significant improvements in testing efficiency.

Patrick Balthrop, CEO of Luminex, said: "Automation continues to be a top priority for Luminex and our customers. The high testing volumes in the newborn screening market require full sample-to-answer automation for the thousands of specimens processed by each customer per day. We evaluated several different robotic solutions to achieve this full automation for our xMAP technology and determined that Tecan was the best option available for this application. We have had a very effective relationship with Tecan and we are proud to be partnered with them in this effort."


About Tecan

Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics. The company specializes in the development, production and distribution of instruments and automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, forensic and diagnostic laboratories. As an original equipment manufacturer, Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2009, Tecan generated sales of CHF 392 million (USD 361.2 million; EUR 259.6 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TK: TECN/Reuters: TECZn.S/ ISIN CH0012100191).

About Luminex Corporation

Luminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the diagnostic and life sciences industries. The Company's xMAP® multiplex solutions include an open- architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics markets. The Company's xMAP Technology is sold worldwide and is already in use in leading clinical laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex Corporation or xMAP Technology can be obtained at www.luminexcorp.com.


For further information:

Tecan Group

Martin Braendle
Head of Corporate Communications & Investor Relations
Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89
investor@tecan.com
www.tecan.com

Luminex Contacts:
Luminex Corporate Contact:
Harriss T. Currie
Vice President, Finance and Chief Financial Officer
512.219.8020
hcurrie@luminexcorp.com

Matthew Scalo
Sr. Director Investor Relations
512.219.8020
mscalo@luminexcorp.com

Luminex Media Contact:
Aaron DeLucia
512.241.2249
aaron.delucia@porternovelli.com


[HUG#1450913]



--- End of Message ---

Tecan Group AG Seestrasse 103 Männedorf Switzerland

ISIN: CH0012100191;

Press Release (PDF): http://hugin.info/100384/R/1450913/392318.pdf




This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and
    other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
     originality of the information contained therein.

Source: Tecan Group AG via Thomson Reuters ONE





Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES